United States
Print page content Print
Increase text size Decrease text size
Text Size
Cytopoint logo
Cytopoint Professional Efficacy Skin Healing success

CYTOPOINT™ gives damaged skin a chance to heal
after 1 injection1

*Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1

Significantly different compared to placebo (P≤0.05).

Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

Reference: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis LLC.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
Zoetis Services LLC. All rights reserved. CYT-00090

STUDY DESIGN

A single 2.0 mg/kg dose of CYTOPOINT (n=50) or placebo (n=52) was administered subcutaneously on Day 0 in this randomized, double-blind, placebo-controlled study of dogs diagnosed with atopic dermatitis. The primary effectiveness endpoints were treatment success in pruritus as assessed by owners on a VAS (success defined as a ≥20 mm reduction in pruritus scores compared to Day 0) and by investigators with CADESl-03 (success defined as a ≥50% decrease in CADESl-03 score compared to Day 0).1